A History of Long-Term Proton Pump Inhibitors Reduces the Serum Calcium and Magnesium Levels Irrespective of Parathyroid Hormone
Keywords:
Rheumatoid Arthritis, Parathyroid Hormone, Calcium, Magnesium, SeverityAbstract
Proton pump inhibitors (PPIs) are drugs used o reduce the stomach acidity caused by the treatment with anti-inflammatory drugs in some rheumatoid arthritis (RA) patients. The effect of these drugs on the parathyroid hormones (PTH) and related electrolytes (calcium, magnesium, and phosphate is not studied yet. The present study aims to accomplish this goal by measurements of the mentioned serum parameters in 70 RA patients treated with PPIs (PPI group) and comparing their results with 70 not treated with PPIs (No PPI group). The results showed a significant increase in serum calcium and magnesium levels in the PPI group compared with the No-PPI group. While no significant difference in the PTH level between groups. The severe RA group showed a significant increase in WBCs counts compared with the mildmoderate RA group indicating the role of inflammation as an indicator of severity. Serum calcium showed a significant correlation with the duration of the disease and a negative correlation with the disease activity. Serum intact-PTH has a significant correlation with serum inorganic phosphate, and inversely with serum calcium. Serum calcium has an inverse correlation with the ESR value. The results showed a significant correlation between calcium and hemoglobin. Receiver operating characteristic (ROC) for differentiation between severe and mild RF indicates that the increase in serum PTH level to a value higher than the cutoff value (55.50 pg/ml), indicates significantly that the patients may have a severe RA form in a sensitivity of 60.9% and specificity of 61.7%
Downloads
References
Abboud B, Daher R, Boujaoude J. Digestive manifestations of
parathyroid disorders. World J Gastroenterol 2011; 17(36): 4063-
Akgul O, Di Cesare Mannelli L, Vullo D, Angeli A, Ghelardini C,
Bartolucci G, et al. Discovery of novel nonsteroidal anti¬
inflammatory drugs and carbonic anhydrase inhibitors hybrids
(NSAIDs-CAIs) for the management of rheumatoid arthritis.
Journal of Medicinal Chemistry 2018; 61(11): 4961-4977
Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, 3rd,
et al. 2010 Rheumatoid arthritis classification criteria: an American
College of Rheumatology/European League Against Rheumatism
collaborative initiative. Arthritis Rheum 2010; 62(9): 2569-2581
Aletaha D, Smolen JS. Diagnosis and management of rheumatoid
arthritis a review. Jama 2018; 320(13): 1360-1372
Ali HH, Yaseen MM, Al-Rawi KF, Alaaraji SFT, Al-Hakeim HK.
Inflammatory and bone biomarkers/composites as a predictive tool
for clinical characteristics of rheumatoid arthritis patients. Acta
Biologica Szegediensis 283 271 65 2 2022
Anderson PH. Vitamin D Activity and Metabolism in Bone. Curr
Osteoporos Rep 2017; 15(5): 443-449
Annamalai R, Kumar AN. Study of biochemical profile and 25-hydroxy
Vitamin D association with disease activity in rheumatoid arthritis
patients. Journal of Orthopaedics and Allied Sciences 2018; 6(1): 17
Brune K, Patrignani P. New insights into the use of currently available
non-steroidal anti-inflammatory drugs. J Pain Res 2015; 8 105-118
Brzustewicz E, Henc I, Daca A, Szarecka M, Sochocka-Bykowska M,
Witkowski J, et al. Autoantibodies, C-reactive protein, erythrocyte
sedimentation rate and serum cytokine profiling in monitoring of
early treatment. Cent Eur J Immunol 2017a; 42(3): 259-268
Brzustewicz E, Henc I, Daca A, Szarecka M, Sochocka-Bykowska M,
Witkowski J, et al. Autoantibodies, C-reactive protein, erythrocyte
sedimentation rate and serum cytokine profiling in monitoring of
early treatment. Central-european Journal of Immunology 2017b;
(3): 259
Chavan VU, Ramavataram D, Patel PA, Rupani MP. Evaluation of serum
magnesium, lipid profile and various biochemical parameters as risk
factors of cardiovascular diseases in patients with rheumatoid
arthritis. Journal of clinical and diagnostic research: JCDR 2015; 9(4):
BC01
Corbetta S. Normocalcemic Hyperparathyroidism. Front Horm Res
; 51 23-39
Cortes YE, Moses L. Magnesium disturbances in critically ill patients.
Compend Contin Educ Vet 2007; 29(7): 420-427
Crofford LJ. Use of NSAIDs in treating patients with arthritis. Arthritis
research & therapy 2013; 15(3): 1-10
Dar L, Tiosano S, Watad A, Bragazzi NL, Zisman D, Comaneshter D, et
al. Are obesity and rheumatoid arthritis interrelated? Int J Clin Pract
; 72(1
de Baaij JH, Hoenderop JG, Bindels RJ. Magnesium in man implications
for health and disease. Physiol Rev 2015; 95(1): 1-46
Del-Pino M, Sanz EJ. Analysis of deprescription strategies of proton
pump inhibitors in primary care: a narrative review. Primary Health
Care Research & Development 2023; 24 el4
Fautrel B, Alten R, Kirkham B, de la Torre I, Durand F, Barry J, et al. Call
for action: howto improve use of patient-reported outcomes to guide
clinical decision making in rheumatoid arthritis. Rheumatology
international 2018; 38(6): 935-947
Foley CS, Moore EC, Milas M, Berber E, Shin J, Siperstein AE. Receiver
operating characteristic analysis of intraoperative parathyroid
hormone monitoring to determine optimum sensitivity and
specificity: analysis of 896 cases. Endocrine Practice 2019; 25(11):
-1126
Freedberg DE, Kim LS, Yang Y-X. The risks and benefits of long-term
use of proton pump inhibitors:expert review and best practice advice
from the American Gastroenterological Association.
Gastroenterology 2017; 152(4): 706-715
Ganguly A. Determination of the impact of functional instability of
parathyroid hormone and the calcium-phosphorus ratio as risk
factors during osteoarthritic disorders using receiver operating
characteristic curves. Int. Arch. BioMed. Clin. Res 2017; 3 47-52Geiger H, Wanner C Magnesium in disease. Clin Kidney J 2012; 5(Suppl
: i25-i38
Gommers LM, Ederveen TH, van der Wijst J, Overmars-Bos C, Kortman
GA, Boekhorst J, et al. Low gut microbiota diversity and dietary
magnesium intake are associated with the development of PPI
induced hypomagnesemia. The FASEB Journal 2019; 33(10): 11235-
Grund B, Sabin C. Analysis of biomarker data:logs, odds ratios and ROC
curves. Current Opinion in HIV and AIDS 2010; 5(6): 473
Hardy P, Sechet A, Hottelart C, Oprisiu R, Abighanem O, Said S, et al.
Inhibition of gastric secretion by omeprazole and efficiency of
calcium carbonate on the control of hyperphosphatemia in patients
on chronic hemodialysis. Artificial organs 1998; 22(7): 569-573
Hess M, Hoenderop J, Bindels R, Drenth J. Systematic review:
hypomagnesaemia induced by proton pump inhibition. Alimentary
pharmacology & therapeutics 2012; 36(5): 405-413
Hsieh PH, Wu O, Geue C, McIntosh E, McInnes IB, Siebert S. Economic
burden of rheumatoid arthritis: a systematic review of literature in
biologic era. Ann Rheum Dis 2020; 79(6): 771-777
Jahnavi K, Reddy PP, Vasudha B, Narender B. Non-steroidal anti¬
inflammatory drugs: an overview. Journal of Drug Delivery and
Therapeutics 2019; 9(l-s): 442-448
Jena AB, Sun E, Goldman DP. Confounding in the association of proton
pump inhibitor use with risk of community-acquired pneumonia. J
Gen Intern Med 2013; 28(2): 223-230
Khadim RM, Al-Fartusie FS. Evaluation of some trace elements and
antioxidants in sera of patients with rheumatoid arthritis: a case¬
control study. Clinical Rheumatology 2023; 42(1): 55-65
Kim JW, Suh CH.Systemic Manifestations and Complications in Patients
with Rheumatoid Arthritis. J Clin Med 2020; 9(6
Kocsis I, Arato A, Bodanszky H, Szonyi L, Szabo A, Tulassay T, et al.
Short-term omeprazole treatment does not influence biochemical
parameters of bone turnover in children. Calcified tissue
international 2002; 71(2): 129-132
Kohler BM, Gunther J, Kaudewitz D, Lorenz H-M. Current therapeutic
options in the treatment of rheumatoid arthritis. Journal of clinical
medicine 2019; 8(7): 938
Larsson SC, Burgess S, Michaelsson K. Association of genetic variants
related to serum calcium levels with coronary artery disease and
myocardial infarction. Jama 2017; 318(4): 371-380
Levy EI, Salvatore S, Vandenplas Y, de Winter JP. (2020). Prescription of
acid inhibitors in infants: an addiction hard to break (Vol. 179, pp.
-1961): Springer
Lin YJ, Anzaghe M, Schiilke S. Update on the Pathomechanism,
Diagnosis, and Treatment Options for Rheumatoid Arthritis. Cells
; 9(4
Lucia M, Isabela S, Minerva G. Changes of serum magnesium level in
patients with rheumatoid arthritis stage I-II, before treatment. Med
Con 2011; 6(2): 9-16
Mackenzie-Feder J, Sirrs S, Anderson D, Sharif J Khan A. Primary
hyperparathyroidism: an overview. Int J Endocrinol 2011; 2011
Mahdi KS, Hussein DM, Dabbi MA, Al-Imari MJ, Obaid RH, Hamad
MH, et al. The Correlation Study between Rheumatoid Arthritis and
Obesity in Babylon Province. The Egyptian Journal of Hospital
Medicine 2023; 90(1): 401-406
Naito Y, Kashiwagi K, Takagi T, Andoh A, Inoue R. Intestinal dysbiosis
secondary to proton-pump inhibitor use. Digestion 2018; 97(2): 195-
Nehra AK, Alexander JA, Loftus CG, Nehra V. (2018). Proton pump
inhibitors: review of emerging concerns. Paper presented at the
Mayo Clinic Proceedings
Nielsen FH. Magnesium deficiency and increased inflammation: current
perspectives. Journal of inflammation research 2018; 11 25-34
Pereira DdC, Lima RPA, de Lima RT, Goncalves MdCR, de Morais LCSL,
Franceschini SdCC, et al. Association between obesity and calcium:
phosphorus ratio in the habitual diets of adults in a city of
Northeastern Brazil: an epidemiological study. Nutrition Journal
; 12(1): 1-11
Poddar A, Behera DD, Ray S. Serum alkaline phosphatase activity &
serum calcium levels: an assessment tool for disease activity in
rheumatoid arthritis. IJBAMR 2016; 5(4): 1324
Ramavataram D. Drinking water-hard or soft. Natl J Community Med
; 3(1): 1-2
Reid IR, Birstow SM, Bolland MJ. Calcium and cardiovascular disease.
Endocrinology and metabolism 2017; 32(3): 339-349
Rosique-Esteban N, Guasch-Ferre M, Hernandez-Alonso P, SalasSalvado J. Dietary magnesium and cardiovascular disease: a review
with emphasis in epidemiological studies. Nutrients 2018; 10(2): 168
Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, et
al. The 2011 report on dietary reference intakes for calcium and
vitamin D from the Institute of Medicine: what clinicians need to
know. The Journal of Clinical Endocrinology & Metabolism 2011;
(1): 53-58
Rossini M, Bagnato G, Frediani B, lagnocco A, G LAM, Minisola G, et al.
Relationship of focal erosions, bone mineral density, and parathyroid
hormone in rheumatoid arthritis J Rheumatol 2011a; 38(6):997-1002
Rossini M, Bagnato G, Frediani B, lagnocco A, La Montagna G, Minisola
G, et al. Relationship of focal erosions, bone mineral density, and
parathyroid hormone in rheumatoid arthritis. The Journal of
rheumatology 2011b 1002 997 6 38
Rossini M, Viapiana O, Adami S, Fracassi E, Idolazzi L, Dartizio C, et al.
In patients with rheumatoid arthritis, Dickkopf-1 serum levels are
correlated with parathyroid hormone, bone erosions and bone
mineral density. Clin Exp Rheumatol 83 77 1 33 2015
Roux C, Briot K, Gossec L, Kolta S, Blenk T, Felsenberg D, et al. Increase
in vertebral fracture risk in postmenopausal women using
omeprazole. Calcified tissue international 2009; 84 13-19
Safiri S, Kolahi AA, Hoy D, Smith E, Bettampadi D, Mansournia MA, et
al. Global, regional and national burden of rheumatoid arthritis
-2017: a systematic analysis of the Global Burden of Disease
study 2017. Ann Rheum Dis 2019; 78(11): 1463-1471
Sakyi SA, Owusu-Yeboah M, Obirikorang C, Dadzie Ephraim RK,
Kwarteng A, Opoku S, et al. Profiling vitamin D, its mediators and
proinflammatory cytokines in rheumatoid arthritis: A case-control
study. Immun Inflamm Dis 2022; 10(8): e676
Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010
1094 9746 376
Shahi A, Aslani S, Ataollahi M, Mahmoudi M. The role of magnesium in
different inflammatory diseases. Inflammopharmacology 2019;
(4): 649-661
Shandookh QJ, Albedri K, Abdullateef NN. Effect of Chronic Use of
Proton Pump Inhibitors on Bone Mineral Density. Iraqi
Postgraduate Medical Journal 2022; 21(2
Siouti E, Andreakos E. The many facets of macrophages in rheumatoid
arthritis. Biochemical pharmacology 2019; 165 152-169
Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery
P, et al. Treating rheumatoid arthritis to target: 2014 update of the
recommendations of an international task force. Ann Rheum Dis
; 75(1): 3-15
Takeno M, Kitagawa S, Yamanaka J, Teramoto M, Tomita H, Shirai N, et
al. 5-Hydroxy-2-methylpyridine Isolated from Cigarette Smoke
Condensate Aggravates Collagen-Induced Arthritis in Mice. Biol
Pharm Bull 2018; 41(6): 877-884Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD. Use of
proton pump inhibitors and risk of osteoporosis-related fractures.
Cmaj 2008; 179(4): 319-326
Targownik LE, Metge C, Roos L, Leung S. The prevalence of and the
clinical and demographic characteristics associated with highintensity proton pump inhibitor use. Official journal of the American
College of Gastroenterology| ACG 2007; 102(5): 942-950
Workinger JL, Doyle R, Bortz J. Challenges in the diagnosis of
magnesium status. Nutrients 2018; 10(9): 1202
Yap HY, Tee SZ, Wong MM, Chow SK, Peh SC, Teow SY. Pathogenic
Role of Immune Cells in Rheumatoid Arthritis: Implications in
Clinical Treatment and Biomarker Development. Cells 2018; 7(10
Yu EW, Blackwell T, Ensrud KE, Hillier TA, Lane NE, Orwoll E, et al.
Acid-suppressive medications and risk of bone loss and fracture in
older adults. Calcified tissue international 2008; 83 251-259
Yuan J, Zhang C, Sparks JA, Malspeis S, Tsoi KK, Kim JH, et al. Regular
use of proton pump inhibitor and risk of rheumatoid arthritis in
women: a prospective cohort study. Aliment Pharmacol Ther 2020;
(3): 449-458
Zaidi M. Modularity of osteoclast behaviour and “mode-specific”
inhibition of osteoclast function. Bioscience Reports 1990; 10 547-
Downloads
Published
Issue
Section
License
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
